

Yao Wang

Mentor: Dr. Saneel Kulkarni

Title: *Report of Application of Inpatient Free Trial Program at St Alexius Hospital*

Four key elements of St. Alexius Hospital's Mission and Values are: the Teachings of Jesus Christ, Compassion, Care for the Poor and Partnership. St. Alexius's participation in the Inpatient Free Trial Program would help to further its mission and to demonstrate its values. The beneficiaries of this program would be psychiatric patients: i.e., the sick, who are not well-equipped to buy it: i.e., the poor. St. Alexius cooperation: i.e., Partnership, with Alkermes Inc. and Janssen Inc. will help to provide psychiatric medication at no up-front cost to schizophrenic patients.

The Inpatient Free Trial Program is to provide hospitalized patients with up to 2 free trial units per calendar year of Aristada® (441 mg, 662 mg, 882 mg, and 1064 mg), Aristada Initio® (675 mg), or Invega Sustenna® (156 mg and 234 mg) at St Alexius Hospital. Currently, the St Alexius Hospital PT committee has approved this only for patients initiating on the doses. Any exceptions would need to be approved by the Director of Pharmacy or the PT committee chair.

Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient's lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. Some 1st and 2nd generation antipsychotics are available in LAI formulations. These include haloperidol, aripiprazole, paliperidone, and risperidone. At St. Alexius Hospital Aristada® (aripiprazole lauroxil), Aristada Initio® (aripiprazole lauroxil), Abilify Maintena® (aripiprazole), and Invega Sustenna® (paliperidone) are non-formulary medications, while Haldol Decanoate® (haloperidol) is a formulary medication.